|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0021747,
umls-concept:C0030705,
umls-concept:C0033204,
umls-concept:C0035525,
umls-concept:C0087111,
umls-concept:C0205466,
umls-concept:C0220847,
umls-concept:C0870071,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-22
|
|
pubmed:abstractText |
A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of response are lower in patients coinfected with HCV and human immunodeficiency virus (HIV), the recognition of predictors of response is a high priority in this population.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:BarreiroPabloP,
pubmed-author:BenitoJose MiguelJM,
pubmed-author:CalvinoAidaA,
pubmed-author:CaruzAntonioA,
pubmed-author:MacíasJuanJ,
pubmed-author:McHutchisonJohnJ,
pubmed-author:MedranoJoseJ,
pubmed-author:NaggieSusannaS,
pubmed-author:NeukamKarinK,
pubmed-author:PinedaJuan AntonioJA,
pubmed-author:RallónNormaN,
pubmed-author:ResinoSalvadorS,
pubmed-author:RiveroAntonioA,
pubmed-author:Sánchez-PiedraCarlosC,
pubmed-author:SorianoVincentV,
pubmed-author:VispoEugeniaE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1209-16
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20964522-Adult,
pubmed-meshheading:20964522-Antiviral Agents,
pubmed-meshheading:20964522-Cohort Studies,
pubmed-meshheading:20964522-Female,
pubmed-meshheading:20964522-HIV Infections,
pubmed-meshheading:20964522-Hepacivirus,
pubmed-meshheading:20964522-Hepatitis C, Chronic,
pubmed-meshheading:20964522-Humans,
pubmed-meshheading:20964522-Interferon Type I,
pubmed-meshheading:20964522-Interleukins,
pubmed-meshheading:20964522-Logistic Models,
pubmed-meshheading:20964522-Male,
pubmed-meshheading:20964522-Middle Aged,
pubmed-meshheading:20964522-Models, Statistical,
pubmed-meshheading:20964522-Polyethylene Glycols,
pubmed-meshheading:20964522-Polymorphism, Single Nucleotide,
pubmed-meshheading:20964522-Predictive Value of Tests,
pubmed-meshheading:20964522-ROC Curve,
pubmed-meshheading:20964522-Recombinant Proteins,
pubmed-meshheading:20964522-Reproducibility of Results,
pubmed-meshheading:20964522-Ribavirin,
pubmed-meshheading:20964522-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Hospital Carlos III, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
